Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study.
Trovato E, Bonifati C, Ribero S, Scalvenzi M, Narcisi A, Cuccia A, Panasiti V, Richetta AG, Pagnanelli G, Peris K, Rongioletti F, Satolli F, Bardazzi F, Borghi A, Carrera C, Galluzzo M, Lasagni C, Moretti G, Romanelli M, Cozzani E, Guarneri C, Venturini M, Bongiorno MR, Prignano F, Di Lernia V, Taviti F, Persechino S, De Pasquale R, Colonna F, Talamonti M, Costanzo A.
Trovato E, et al.
Dermatol Ther (Heidelb). 2026 Feb 19. doi: 10.1007/s13555-026-01676-3. Online ahead of print.
Dermatol Ther (Heidelb). 2026.
PMID: 41712057